2018-2023 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Report

August 2018 | 161 pages | ID: 2A91C077F97EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Alpha 1 Antitrypsin Deficiency Treatment market for 2018-2023.
Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma.
The discovery of the structure and function of the AAT protein and the subsequent isolation and purification thereof have made possible alternative therapies aimed at preventing the progression of related pulmonary diseases (so-called 'additional therapies'). The isolation of this gene and the advancement of gene therapy have further increased the possibility of specific treatment. Most specific treatments for AAT deficiency aim to increase plasma AAT levels (and thus elevated AAT concentrations in the interstitial lung) above the protection threshold. Other experimental therapeutic approaches attempt to interfere with the production of abnormal AAT proteins or to inhibit the polymerization of abnormal AAT proteins and to promote the secretion of AAT from hepatocytes. For patients with end-stage lung disease or liver disease, organ transplantation is another treatment option.
Currently, the most direct and effective way to increase AAT levels in plasma and interstitial lung is by intravenous infusion of pooled alpha-1 antitrypsin (pAAT).

Over the next five years, LPI(LP Information) projects that Alpha 1 Antitrypsin Deficiency Treatment will register a 9.0% CAGR in terms of revenue, reach US$ 1980 million by 2023, from US$ 1190 million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Alpha 1 Antitrypsin Deficiency Treatment market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

• Augmentation Therapy
• Bronchodilators
• Corticosteroids
• Oxygen Therapy

Segmentation by application:

• Hospitals
• Specialty Clinics
• Pharmacies

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

• Pfizer
• Baxter
• AstraZeneca
• Grifols
• Teva Pharmaceutical Industries
• Boehringer Ingelheim
• Kamada Ltd
• GlaxoSmithKline
• CSL Behring
• Shire
• LFB Biomedicaments
• Abeona Therapeutics
• Biogen
• Applied Genetic Technologies
• Baxalta
• Arrowhead Research Corporation
• ProBioGen
• Chiesi Pharmaceuticals
• Curaxys
• ProMetic Life Sciences

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

RESEARCH OBJECTIVES

• To study and analyze the global Alpha 1 Antitrypsin Deficiency Treatment consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Alpha 1 Antitrypsin Deficiency Treatment market by identifying its various subsegments.
• Focuses on the key global Alpha 1 Antitrypsin Deficiency Treatment manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Alpha 1 Antitrypsin Deficiency Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the consumption of Alpha 1 Antitrypsin Deficiency Treatment submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

2018-2023 GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT CONSUMPTION MARKET REPORT

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption 2013-2023
  2.1.2 Alpha 1 Antitrypsin Deficiency Treatment Consumption CAGR by Region
2.2 Alpha 1 Antitrypsin Deficiency Treatment Segment by Type
  2.2.1 Augmentation Therapy
  2.2.2 Bronchodilators
  2.2.3 Corticosteroids
  2.2.4 Oxygen Therapy
2.3 Alpha 1 Antitrypsin Deficiency Treatment Consumption by Type
  2.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Type (2013-2018)
  2.3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Type (2013-2018)
  2.3.3 Global Alpha 1 Antitrypsin Deficiency Treatment Sale Price by Type (2013-2018)
2.4 Alpha 1 Antitrypsin Deficiency Treatment Segment by Application
  2.4.1 Hospitals
  2.4.2 Specialty Clinics
  2.4.3 Pharmacies
2.5 Alpha 1 Antitrypsin Deficiency Treatment Consumption by Application
  2.5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application (2013-2018)
  2.5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Value and Market Share by Application (2013-2018)
  2.5.3 Global Alpha 1 Antitrypsin Deficiency Treatment Sale Price by Application (2013-2018)

3 GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT BY PLAYERS

3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Players
  3.1.1 Global Alpha 1 Antitrypsin Deficiency Treatment Sales by Players (2016-2018)
  3.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Players (2016-2018)
3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players
  3.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2016-2018)
  3.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2016-2018)
3.3 Global Alpha 1 Antitrypsin Deficiency Treatment Sale Price by Players
3.4 Global Alpha 1 Antitrypsin Deficiency Treatment Manufacturing Base Distribution, Sales Area, Product Types by Players
  3.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Manufacturing Base Distribution and Sales Area by Players
  3.4.2 Players Alpha 1 Antitrypsin Deficiency Treatment Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT BY REGIONS

4.1 Alpha 1 Antitrypsin Deficiency Treatment by Regions
  4.1.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption by Regions
  4.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Value by Regions
4.2 Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth
4.3 APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth
4.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth
4.5 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth

5 AMERICAS

5.1 Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption by Countries
  5.1.1 Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption by Countries (2013-2018)
  5.1.2 Americas Alpha 1 Antitrypsin Deficiency Treatment Value by Countries (2013-2018)
5.2 Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption by Type
5.3 Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption by Countries
  6.1.1 APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption by Countries (2013-2018)
  6.1.2 APAC Alpha 1 Antitrypsin Deficiency Treatment Value by Countries (2013-2018)
6.2 APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption by Type
6.3 APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment by Countries
  7.1.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption by Countries (2013-2018)
  7.1.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Value by Countries (2013-2018)
7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption by Type
7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment by Countries
  8.1.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption by Countries (2013-2018)
  8.1.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Value by Countries (2013-2018)
8.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption by Type
8.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 MARKETING, DISTRIBUTORS AND CUSTOMER

10.1 Sales Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
10.2 Alpha 1 Antitrypsin Deficiency Treatment Distributors
10.3 Alpha 1 Antitrypsin Deficiency Treatment Customer

11 GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET FORECAST

11.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Forecast (2018-2023)
11.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecast by Regions
  11.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Forecast by Regions (2018-2023)
  11.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Value Forecast by Regions (2018-2023)
  11.2.3 Americas Consumption Forecast
  11.2.4 APAC Consumption Forecast
  11.2.5 Europe Consumption Forecast
  11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
  11.3.1 United States Market Forecast
  11.3.2 Canada Market Forecast
  11.3.3 Mexico Market Forecast
  11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
  11.4.1 China Market Forecast
  11.4.2 Japan Market Forecast
  11.4.3 Korea Market Forecast
  11.4.4 Southeast Asia Market Forecast
  11.4.5 India Market Forecast
  11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
  11.5.1 Germany Market Forecast
  11.5.2 France Market Forecast
  11.5.3 UK Market Forecast
  11.5.4 Italy Market Forecast
  11.5.5 Russia Market Forecast
  11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
  11.6.1 Egypt Market Forecast
  11.6.2 South Africa Market Forecast
  11.6.3 Israel Market Forecast
  11.6.4 Turkey Market Forecast
  11.6.5 GCC Countries Market Forecast
11.7 Global Alpha 1 Antitrypsin Deficiency Treatment Forecast by Type
11.8 Global Alpha 1 Antitrypsin Deficiency Treatment Forecast by Application

12 KEY PLAYERS ANALYSIS

12.1 Pfizer
  12.1.1 Company Details
  12.1.2 Alpha 1 Antitrypsin Deficiency Treatment Product Offered
  12.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
  12.1.4 Main Business Overview
  12.1.5 Pfizer News
12.2 Baxter
  12.2.1 Company Details
  12.2.2 Alpha 1 Antitrypsin Deficiency Treatment Product Offered
  12.2.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
  12.2.4 Main Business Overview
  12.2.5 Baxter News
12.3 AstraZeneca
  12.3.1 Company Details
  12.3.2 Alpha 1 Antitrypsin Deficiency Treatment Product Offered
  12.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
  12.3.4 Main Business Overview
  12.3.5 AstraZeneca News
12.4 Grifols
  12.4.1 Company Details
  12.4.2 Alpha 1 Antitrypsin Deficiency Treatment Product Offered
  12.4.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
  12.4.4 Main Business Overview
  12.4.5 Grifols News
12.5 Teva Pharmaceutical Industries
  12.5.1 Company Details
  12.5.2 Alpha 1 Antitrypsin Deficiency Treatment Product Offered
  12.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
  12.5.4 Main Business Overview
  12.5.5 Teva Pharmaceutical Industries News
12.6 Boehringer Ingelheim
  12.6.1 Company Details
  12.6.2 Alpha 1 Antitrypsin Deficiency Treatment Product Offered
  12.6.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
  12.6.4 Main Business Overview
  12.6.5 Boehringer Ingelheim News
12.7 Kamada Ltd
  12.7.1 Company Details
  12.7.2 Alpha 1 Antitrypsin Deficiency Treatment Product Offered
  12.7.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
  12.7.4 Main Business Overview
  12.7.5 Kamada Ltd News
12.8 GlaxoSmithKline
  12.8.1 Company Details
  12.8.2 Alpha 1 Antitrypsin Deficiency Treatment Product Offered
  12.8.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
  12.8.4 Main Business Overview
  12.8.5 GlaxoSmithKline News
12.9 CSL Behring
  12.9.1 Company Details
  12.9.2 Alpha 1 Antitrypsin Deficiency Treatment Product Offered
  12.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
  12.9.4 Main Business Overview
  12.9.5 CSL Behring News
12.10 Shire
  12.10.1 Company Details
  12.10.2 Alpha 1 Antitrypsin Deficiency Treatment Product Offered
  12.10.3 Shire Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
  12.10.4 Main Business Overview
  12.10.5 Shire News
12.11 LFB Biomedicaments
12.12 Abeona Therapeutics
12.13 Biogen
12.14 Applied Genetic Technologies
12.15 Baxalta
12.16 Arrowhead Research Corporation
12.17 ProBioGen
12.18 Chiesi Pharmaceuticals
12.19 Curaxys
12.20 ProMetic Life Sciences

13 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Alpha 1 Antitrypsin Deficiency Treatment
Table Product Specifications of Alpha 1 Antitrypsin Deficiency Treatment
Figure Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered
Figure Market Research Methodology
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth Rate 2013-2023 (K Units)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Value Growth Rate 2013-2023 ($ Millions)
Table Alpha 1 Antitrypsin Deficiency Treatment Consumption CAGR by Region 2013-2023 ($ Millions)
Figure Product Picture of Augmentation Therapy
Table Major Players of Augmentation Therapy
Figure Product Picture of Bronchodilators
Table Major Players of Bronchodilators
Figure Product Picture of Corticosteroids
Table Major Players of Corticosteroids
Figure Product Picture of Oxygen Therapy
Table Major Players of Oxygen Therapy
Table Global Consumption Sales by Type (2013-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Type (2013-2018)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Type (2013-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2013-2018) ($ million)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Type (2013-2018) ($ Millions)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Type (2013-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Sale Price by Type (2013-2018)
Figure Alpha 1 Antitrypsin Deficiency Treatment Consumed in Hospitals
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Market: Hospitals (2013-2018) (K Units)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Market: Hospitals (2013-2018) ($ Millions)
Figure Global Hospitals YoY Growth ($ Millions)
Figure Alpha 1 Antitrypsin Deficiency Treatment Consumed in Specialty Clinics
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Market: Specialty Clinics (2013-2018) (K Units)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Market: Specialty Clinics (2013-2018) ($ Millions)
Figure Global Specialty Clinics YoY Growth ($ Millions)
Figure Alpha 1 Antitrypsin Deficiency Treatment Consumed in Pharmacies
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Market: Pharmacies (2013-2018) (K Units)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Market: Pharmacies (2013-2018) ($ Millions)
Figure Global Pharmacies YoY Growth ($ Millions)
Table Global Consumption Sales by Application (2013-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application (2013-2018)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application (2013-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Value by Application (2013-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Application (2013-2018)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Application (2013-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Sale Price by Application (2013-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales by Players (2016-2018) (K Units)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Players (2016-2018)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Players in 2016
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Players in 2017
Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2016-2018) ($ Millions)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2016-2018)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players in 2016
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players in 2017
Table Global Alpha 1 Antitrypsin Deficiency Treatment Sale Price by Players (2016-2018)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Sale Price by Players in 2017
Table Global Alpha 1 Antitrypsin Deficiency Treatment Manufacturing Base Distribution and Sales Area by Players
Table Players Alpha 1 Antitrypsin Deficiency Treatment Products Offered
Table Alpha 1 Antitrypsin Deficiency Treatment Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Consumption by Regions 2013-2018 (K Units)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Regions 2013-2018
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Regions 2013-2018
Table Global Alpha 1 Antitrypsin Deficiency Treatment Value by Regions 2013-2018 ($ Millions)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Regions 2013-2018
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Regions 2013-2018
Figure Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption 2013-2018 (K Units)
Figure Americas Alpha 1 Antitrypsin Deficiency Treatment Value 2013-2018 ($ Millions)
Figure APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption 2013-2018 (K Units)
Figure APAC Alpha 1 Antitrypsin Deficiency Treatment Value 2013-2018 ($ Millions)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption 2013-2018 (K Units)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Value 2013-2018 ($ Millions)
Figure Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption 2013-2018 (K Units)
Figure Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Value 2013-2018 ($ Millions)
Table Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption by Countries (2013-2018) (K Units)
Table Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Countries (2013-2018)
Figure Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Countries in 2017
Table Americas Alpha 1 Antitrypsin Deficiency Treatment Value by Countries (2013-2018) ($ Millions)
Table Americas Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Countries (2013-2018)
Figure Americas Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Countries in 2017
Table Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption by Type (2013-2018) (K Units)
Table Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Type (2013-2018)
Figure Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Type in 2017
Table Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption by Application (2013-2018) (K Units)
Table Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application (2013-2018)
Figure Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application in 2017
Figure United States Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure United States Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure Canada Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Canada Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure Mexico Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Mexico Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Table APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption by Countries (2013-2018) (K Units)
Table APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Countries (2013-2018)
Figure APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Countries in 2017
Table APAC Alpha 1 Antitrypsin Deficiency Treatment Value by Countries (2013-2018) ($ Millions)
Table APAC Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Countries (2013-2018)
Figure APAC Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Countries in 2017
Table APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption by Type (2013-2018) (K Units)
Table APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Type (2013-2018)
Figure APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Type in 2017
Table APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption by Application (2013-2018) (K Units)
Table APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application (2013-2018)
Figure APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application in 2017
Figure China Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure China Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure Japan Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Japan Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure Korea Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Korea Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure India Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure India Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure Australia Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Australia Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Table Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption by Countries (2013-2018) (K Units)
Table Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Countries (2013-2018)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Countries in 2017
Table Europe Alpha 1 Antitrypsin Deficiency Treatment Value by Countries (2013-2018) ($ Millions)
Table Europe Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Countries (2013-2018)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Countries in 2017
Table Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption by Type (2013-2018) (K Units)
Table Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Type (2013-2018)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Type in 2017
Table Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption by Application (2013-2018) (K Units)
Table Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application (2013-2018)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application in 2017
Figure Germany Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Germany Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure France Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure France Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure UK Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure UK Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure Italy Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Italy Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure Russia Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Russia Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure Spain Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Spain Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Table Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption by Countries (2013-2018) (K Units)
Table Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Countries (2013-2018)
Figure Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Countries in 2017
Table Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Value by Countries (2013-2018) ($ Millions)
Table Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Countries (2013-2018)
Figure Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Value Market Share by Countries in 2017
Table Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption by Type (2013-2018) (K Units)
Table Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Type (2013-2018)
Figure Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Type in 2017
Table Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption by Application (2013-2018) (K Units)
Table Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application (2013-2018)
Figure Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share by Application in 2017
Figure Egypt Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Egypt Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure South Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure South Africa Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure Israel Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Israel Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure Turkey Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure Turkey Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Figure GCC Countries Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth 2013-2018 (K Units)
Figure GCC Countries Alpha 1 Antitrypsin Deficiency Treatment Value Growth 2013-2018 ($ Millions)
Table Alpha 1 Antitrypsin Deficiency Treatment Distributors List
Table Alpha 1 Antitrypsin Deficiency Treatment Customer List
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Growth Rate Forecast (2018-2023) (K Units)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Value Growth Rate Forecast (2018-2023) ($ Millions)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Forecast by Countries (2018-2023) (K Units)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Forecast by Regions
Table Global Alpha 1 Antitrypsin Deficiency Treatment Value Forecast by Countries (2018-2023) ($ Millions)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Value Market Share Forecast by Regions
Figure Americas Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Americas Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure APAC Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure APAC Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure United States Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure United States Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Canada Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Canada Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Mexico Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Mexico Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Brazil Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Brazil Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure China Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure China Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Japan Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Japan Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Korea Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Korea Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure India Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure India Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Australia Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Australia Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Germany Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Germany Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure France Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure France Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure UK Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure UK Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Italy Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Italy Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Russia Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Russia Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Spain Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Spain Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Egypt Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Egypt Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure South Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure South Africa Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Israel Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Israel Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure Turkey Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure Turkey Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Figure GCC Countries Alpha 1 Antitrypsin Deficiency Treatment Consumption 2018-2023 (K Units)
Figure GCC Countries Alpha 1 Antitrypsin Deficiency Treatment Value 2018-2023 ($ Millions)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Forecast by Type (2018-2023) (K Units)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share Forecast by Type (2018-2023)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Value Forecast by Type (2018-2023) ($ Millions)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Value Market Share Forecast by Type (2018-2023)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Forecast by Application (2018-2023) (K Units)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Market Share Forecast by Application (2018-2023)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Value Forecast by Application (2018-2023) ($ Millions)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Value Market Share Forecast by Application (2018-2023)
Table Pfizer Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Pfizer Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Pfizer Alpha 1 Antitrypsin Deficiency Treatment Market Share (2016-2018)
Table Baxter Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Baxter Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Baxter Alpha 1 Antitrypsin Deficiency Treatment Market Share (2016-2018)
Table AstraZeneca Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
Figure AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Market Share (2016-2018)
Table Grifols Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Grifols Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Grifols Alpha 1 Antitrypsin Deficiency Treatment Market Share (2016-2018)
Table Teva Pharmaceutical Industries Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Market Share (2016-2018)
Table Boehringer Ingelheim Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Market Share (2016-2018)
Table Kamada Ltd Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Market Share (2016-2018)
Table GlaxoSmithKline Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
Figure GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Market Share (2016-2018)
Table CSL Behring Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
Figure CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Market Share (2016-2018)
Table Shire Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Shire Alpha 1 Antitrypsin Deficiency Treatment Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Shire Alpha 1 Antitrypsin Deficiency Treatment Market Share (2016-2018)
Table LFB Biomedicaments Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Abeona Therapeutics Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Biogen Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Applied Genetic Technologies Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Baxalta Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Arrowhead Research Corporation Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table ProBioGen Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Chiesi Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Curaxys Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table ProMetic Life Sciences Basic Information, Manufacturing Base, Sales Area and Its Competitors